For decades, the mainstays of kidney protection in diabetes have been ACE inhibitors and ARBs. Recently, a new class of medication has emerged as a powerful tool: non-steroidal mineralocorticoid receptor antagonists (MRAs), with the leading drug being finerenone (brand name Kerendia).
What is Finerenone and How Does it Work?
Finerenone works differently from SGLT2 inhibitors or GLP-1 agonists. It targets the mineralocorticoid receptor (MR). Overactivation of this receptor by the hormone aldosterone contributes to inflammation and fibrosis (scarring) in the kidneys and heart.
By blocking this receptor, finerenone directly reduces these harmful processes. It acts as a potent anti-inflammatory and anti-fibrotic agent within the kidney itself, protecting it from the damage that leads to function decline.
Key Trials (FIDELIO-DKD & FIGARO-DKD): The effectiveness of finerenone was proven in two major clinical trials. They showed that when added to standard care (usually an ACE inhibitor or ARB), finerenone significantly reduced the risk of kidney disease progression and also lowered the risk of cardiovascular events like heart attacks and strokes.
Who is a Candidate for Finerenone?
Finerenone is specifically approved for people with type 2 diabetes and chronic kidney disease. It is designed to be used in combination with an ACE inhibitor or ARB to provide maximum protection.
Your doctor might consider adding finerenone if you have persistent albuminuria (protein in the urine) despite being on an optimized dose of an ACEi/ARB and other protective therapies like an SGLT2 inhibitor.
Monitoring is Crucial: The main side effect of finerenone is hyperkalemia (high potassium levels). Potassium is an essential mineral, but too much can be dangerous for the heart. Before starting finerenone, and regularly during treatment, your doctor will need to monitor your potassium levels and kidney function with blood tests.
Key Takeaway
Finerenone represents a new frontier in kidney protection, tackling inflammation and fibrosis directly. It is not a replacement for existing therapies but a powerful addition for high-risk individuals. Its approval gives doctors another vital tool to slow the progression of diabetic kidney disease and protect cardiovascular health.
Urdu 
English